Prism Pharmaceuticals announced that Nexterone (amiodarone HCl) Premixed Injection has been approved by the FDA for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy. Nexterone Premixed Injection will be available in two dosage strengths: 1.5mg/mL for rapid loading infusion and 1.8mg/mL for subsequent infusion.

For more information call (610) 265-7710 or visit